Marina P. Sanchez

Madrid, MD 28040, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Adeno-Associated Virus-Based Gene Therapy for Lafora Disease in Epm2b-Deficient Mice.

Adeno-Associated Virus-Based Gene Therapy for Lafora Disease in Epm2b-Deficient Mice.

Journal: International journal of molecular sciences

Published: October 29, 2025

Epm2bP71A and Epm2bD148N knock-in mouse models of Lafora disease exhibit distinct and pronounced neurological alterations.

Epm2bP71A and Epm2bD148N knock-in mouse models of Lafora disease exhibit distinct and pronounced neurological alterations.

Journal: Progress in neurobiology

Published: August 26, 2025

Epm2bP71A and Epm2bD148N knock-in mouse models of Lafora disease exhibit distinct and pronounced neurological alterations.

Epm2bP71A and Epm2bD148N knock-in mouse models of Lafora disease exhibit distinct and pronounced neurological alterations.

Journal: Progress in neurobiology

Published: August 26, 2025

Advances in gene therapy for Lafora disease: Intravenous recombinant adeno-associated virus-mediated delivery of EPM2A and EPM2B genes.

Advances in gene therapy for Lafora disease: Intravenous recombinant adeno-associated virus-mediated delivery of EPM2A and EPM2B genes.

Journal: Clinical and translational medicine

Published: July 01, 2025

Neuronal hyperexcitability: A key to unraveling hippocampal synaptic dysfunction in Lafora disease.

Neuronal hyperexcitability: A key to unraveling hippocampal synaptic dysfunction in Lafora disease.

Journal: Epilepsia

Published: June 23, 2025

Identification of Plasma Growth Factors and Cytokines as Diagnostic Biomarkers for the Lafora Form of Progressive Myoclonus Epilepsy.

Identification of Plasma Growth Factors and Cytokines as Diagnostic Biomarkers for the Lafora Form of Progressive Myoclonus Epilepsy.

Journal: International journal of molecular sciences

Published: May 05, 2025

Gene replacement therapy for Lafora disease in the Epm2a -/- mouse model.

Gene replacement therapy for Lafora disease in the Epm2a -/- mouse model.

Journal: bioRxiv : the preprint server for biology

Published: January 03, 2024

Gene therapy for Lafora disease in the Epm2a-/- mouse model.

Gene therapy for Lafora disease in the Epm2a-/- mouse model.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: December 22, 2023

Effect of intracerebroventricular administration of alglucosidase alfa in two mouse models of Lafora disease: Relevance for clinical practice.

Effect of intracerebroventricular administration of alglucosidase alfa in two mouse models of Lafora disease: Relevance for clinical practice.

Journal: Epilepsy research

Published: August 30, 2023

Epm2aR240X knock-in mice present earlier cognitive decline and more epileptic activity than Epm2a-/- mice.

Epm2aR240X knock-in mice present earlier cognitive decline and more epileptic activity than Epm2a-/- mice.

Journal: Neurobiology of disease

Published: December 29, 2022

Early Treatment with Metformin Improves Neurological Outcomes in Lafora Disease.

Early Treatment with Metformin Improves Neurological Outcomes in Lafora Disease.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: September 14, 2022

Beneficial Effects of Metformin on the Central Nervous System, with a Focus on Epilepsy and Lafora Disease.

Beneficial Effects of Metformin on the Central Nervous System, with a Focus on Epilepsy and Lafora Disease.

Journal: International journal of molecular sciences

Published: April 20, 2021

Showing 1-12 of 25

Last Updated: 09/26/2026